Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reiterated by stock analysts at Chardan Capital in a report released on Wednesday,Benzinga reports. They presently have a $14.00 target price on the stock. Chardan Capital’s target price would indicate a potential upside of 191.67% from the company’s previous close.

A number of other research analysts have also recently issued reports on the company. Wall Street Zen cut Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. Finally, Roth Capital began coverage on Coya Therapeutics in a research report on Friday, June 5th. They issued a “buy” rating and a $12.00 price objective for the company. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.33.

Coya Therapeutics Stock Up 3.4%

Shares of NASDAQ COYA opened at $4.80 on Wednesday. Coya Therapeutics has a twelve month low of $3.71 and a twelve month high of $7.75. The stock has a market cap of $112.61 million, a price-to-earnings ratio of -4.17 and a beta of 0.60. The company’s fifty day moving average is $4.86 and its 200-day moving average is $4.67.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The business had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.13 million. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. On average, research analysts anticipate that Coya Therapeutics will post -1.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Alyeska Investment Group L.P. bought a new position in shares of Coya Therapeutics during the fourth quarter worth about $4,640,000. AWM Investment Company Inc. bought a new stake in Coya Therapeutics in the 4th quarter valued at approximately $4,205,000. CM Management LLC boosted its holdings in Coya Therapeutics by 16.7% during the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock worth $2,030,000 after purchasing an additional 50,000 shares during the last quarter. Private Management Group Inc. acquired a new position in shares of Coya Therapeutics during the 4th quarter worth about $1,626,000. Finally, Marshall Wace LLP boosted its position in Coya Therapeutics by 438.8% during the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after purchasing an additional 183,533 shares during the last quarter. 39.75% of the stock is owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.